# Fresenius Medical Care AG (FMS)

> Source: Nexqual · https://nexqual.com/FMS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Fresenius Medical Care AG (FMS), nexqual.com/FMS" · informational, not investment advice.

**Price:** USD 22.23 (+3.11% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 21.56 · day 21.57–22.24 · 52w 20.02–27.4 · market cap $11.8B · NYQ

## Key facts
- 2 of 80 tracked superinvestors hold FMS (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Analysts: Sell (mean 3.57 on a 1–5 scale) (7 analysts), mean target USD 23.82 (range 17.31–37.87).
- Total return with dividends: 1Y -14.1% vs S&P 500 +14.9%; 5Y -27.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.53, revenue estimate $4.92B.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold FMS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 1.00% | $339M | Reduced -0.4% |
| Dodge & Cox Funds | Dodge & Cox | 0.05% | $86.5M | Unchanged |

## Analysts
Consensus Sell (mean 3.57 on a 1–5 scale), 7 analysts; mean target USD 23.82 (low 17.31, high 37.87).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Truist Securities | Target lowered | Hold | $25 → $24 |
| 2026-08-06 | Bernstein | Target raised | Market Perform | $25.5 → $25.8 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -14.1% | -27.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -14.1% | -6.3% |
| Volatility (annualized) | 30.8% | 31.2% |
| Max drawdown | -25.9% (Oct 2025→May 2026) | -62.1% (Oct 2021→Oct 2022) |

## Peers (Medical Care Facilities)
DVA (DaVita Inc.) USD 186.1 +5.25% · EHC (Encompass Health Corporation) USD 126.01 +4.60% · UHS (Universal Health Services, Inc.) USD 188.13 +2.88% · ENSG (The Ensign Group, Inc.) USD 178.35 +2.88% · PACS (PACS Group, Inc.) USD 47.5 +1.58% · CHE (Chemed Corp) USD 520.15 +1.72%

## More
Full page: https://nexqual.com/FMS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name FMS in their own reports (relationship from FMS's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Cytosorbents Corp (CTSO) | 10-K 2026-03-30 | "These partners include Fresenius Medical Care AG, B." |
| partner | Humacyte, Inc. (HUMA) | 10-K 2026-03-27 | "our expectations regarding our strategic partnership with Fresenius Medical Care Holdings, Inc. ("Fresenius Medical Care") to sell, market and distribute our 6 millimeter ATEV for certain specified in…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.53 | $0.56 | -6.4% | $4.92B | 2 |
| Next quarter (ends 2026-12-31) | $0.53 | $0.61 | -13.7% | $5.20B | 2 |
| Current fiscal year (ends 2026-12-31) | $2.07 | $2.46 | -15.8% | $19.49B | 4 |
| Next fiscal year (ends 2027-12-31) | $2.65 | $3.17 | -16.4% | $20.15B | 5 |